NAS:PTI (USA) Also trade in: Germany

Proteostasis Therapeutics Inc

$ 1.05 -0.08 (-7.08%)
Volume: 2,625,264 Avg Vol (1m): 2,250,790
Market Cap $: 53.60 Mil Enterprise Value $: -64,780,000.00
P/E (TTM): 0.00 P/B: 0.43
Earnings Power Value 0
Net Current Asset Value 2.12
Tangible Book 2.44
Projected FCF 0
Median P/S Value 3.34
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 4/10

Current vs industry vs history
Cash-to-Debt No Debt
Equity-to-Asset 0.61
Debt-to-EBITDA -0.24
Piotroski F-Score 1
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -6.58
DISTRESS
GREY
SAFE
Beneish M-Score -2.01
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -1582.21%
WACC -8.63%

Profitability & Growth : 1/10

Current vs industry vs history
Operating Margin % -1415.98
Net Margin % -1385.75
ROE % -91.35
ROA % -67.77
ROC (Joel Greenblatt) % -1671.90
3-Year Total Revenue Growth Rate -13.00
3-Year Total EBITDA Growth Rate -36.50

» PTI's 30-Y Financials

Financials (Next Earnings Date: )

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:PTI

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2836
Compare XTER:PA8 SSE:3055 NAS:AGLE XPAR:POXEL ROCO:3176 ROCO:6547 XBRU:THR XKRX:217730 XPAR:SIGHT NAS:IMDZ XCNQ:MYM ROCO:4743 OSL:SOLON NAS:XOMA NAS:XBIT NAS:NSTG NAS:CNAT NAS:PETX XKRX:115180 XTAE:NTEC
Traded in other countries 42P.Germany
Address 200 Technology Square, 4th Floor, Cambridge, MA, USA, 02139
Proteostasis Therapeutics Inc is a United States-based company engaged in the biotechnology industry. Its core operations comprise of discovery and development of therapeutics that treat diseases caused by an imbalance in protein biosynthesis process in the body. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics. Using this platform, it has identified a new class of small molecules and amplifiers that modulate proteins in the proteostasis network. The products under its development cycle include PTI-428, which is a lead amplifier of CFTR protein. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program.

Ratios

Current vs industry vs history
PB Ratio 0.43
PS Ratio 7.49
EV-to-EBIT 1.01
EV-to-EBITDA 1.04
EV-to-Revenue -14.51
Current Ratio 14.05
Quick Ratio 14.05

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -32.10

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 0.43
Price-to-Median-PS-Value 0.31
Earnings Yield (Joel Greenblatt) % 97.62

More Statistics

Revenue (TTM) (Mil) $ 4.46
EPS (TTM) $ -1.6
Beta -1.87
Volatility % 194.96
52-Week Range $ 1.05 - 10.38
Shares Outstanding (Mil) 50.81

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 1
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N